BIOMAT Database Logo BIOMAT Database Logo

Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study). 1973

R E Bellet, and M J Mastrangelo, and P F Engstrom, and R P Custer

UI MeSH Term Description Entries
D007728 Kupffer Cells Specialized phagocytic cells of the MONONUCLEAR PHAGOCYTE SYSTEM found on the luminal surface of the hepatic sinusoids. They filter bacteria and small foreign proteins out of the blood and dispose of worn out red blood cells. Kupffer Cell,Cell, Kupffer,Cells, Kupffer
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D003562 Cytidine A pyrimidine nucleoside that is composed of the base CYTOSINE linked to the five-carbon sugar D-RIBOSE. Cytosine Ribonucleoside,Cytosine Riboside,Ribonucleoside, Cytosine,Riboside, Cytosine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R E Bellet, and M J Mastrangelo, and P F Engstrom, and R P Custer
A phase I study of 5-azacytidine (NSC-102816).
April 1976, Journal of clinical pharmacology,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and R P Custer
Phase I study of twice weekly 5-azacytidine (NSC-102816).
January 1974, Cancer chemotherapy reports,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and R P Custer
Treatment of acute leukemia with 5-azacytidine (NSC-102816).
January 1973, Cancer chemotherapy reports,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and R P Custer
Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816).
January 1980, Neoplasma,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and R P Custer
Absorption, distribution, and excretion of 5-azacytidine (NSC-102816) in man.
June 1972, Cancer chemotherapy reports,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and R P Custer
5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia.
September 1976, Blood,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and R P Custer
Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days.
January 1975, Cancer chemotherapy reports,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and R P Custer
Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer.
October 1972, Cancer chemotherapy reports,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and R P Custer
Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
January 1975, Cancer chemotherapy reports,
R E Bellet, and M J Mastrangelo, and P F Engstrom, and R P Custer
Development of an intravenous formulation for the unstable investigational cytotoxic nucleosides 5-azacytosine arabinoside (NSC 281272) and 5-azacytidine (NSC 102816).
November 1984, The Journal of pharmacy and pharmacology,
Copied contents to your clipboard!